SkyePharma EGM rejects Thian

The Extraordinary General Meeting (EGM) of SkyePharma has resulted in the rejection of a resolution to see Robert Thian appointed as director.

Both number of shareholders and number of votes went against Mr Thian’s appointment, the choice of disgruntled shareholders to take charge of the pharmaceutical company.

“The EGM is now behind us. We can now get on with running the business for the benefit of all shareholders,” said Dr Jerry Karabelas, SkyePharma’s non-executive chairman.

Dr Karabelas was the source for much of the discontent among shareholders, according to PharmaTimes, which offers that the disgruntled shareholders were looking to “supplant” the non-executive chairman.

The voting over the resolution saw 53 per cent of the votes cast going against the appointment of Mr Thian. In terms of the number of shareholders this represented, just 23 per cent voted for Mr Thian’s appointment as director.

© Adfero Ltd